structural basis agonist partial agonist action beta-adrenergic receptor
beta-adrenergic receptors beta ars g-protein-coupled receptors gpcrs activate intracellular g proteins upon binding catecholamine agonist ligands adrenaline noradrenaline synthetic ligands developed either activate inhibit beta ars treatment asthma hypertension cardiac dysfunction ligands classified either full agonists partial agonists antagonists depending whether cellular response similar native ligand reduced inhibited respectively however structural basis different ligand efficacies unknown present four crystal structures thermo-stabilized turkey meleagris gallopavo beta-adrenergic receptor betaar-m23 bound full agonists carmoterol isoprenaline partial agonists salbutamol dobutamine case agonist binding induces angstrom contraction catecholamine-binding pocket relative antagonist bound receptor full agonists can form hydrogen bonds two conserved serine residues transmembrane helix ser ser partial agonists interact ser superscripts refer ballesteros-weinstein numbering structures provide understanding pharmacological differences different ligand classes illuminating gpcrs function providing solid foundation structure-based design novel ligands predictable efficacies
